LONDON, UK – June 30, 2022 – ºÚÁϲ»´òìÈ (ºÚÁϲ»´òìÈ), a leading global Testing, Inspection and Certification (TIC) company, has appointed Dr. Elisabeth Lackner as Chief Scientific Officer (CSO).
In the newly created CSO role, Dr. Lackner joins the Operating Board ensuring that ºÚÁϲ»´òìÈ is positioned at the leading-edge of scientific thinking. She will be tasked with driving technical excellence and ensuring continued scientific rigor across the global business of more than 7,000 colleagues, with a focus on accelerating growth and services across Life Sciences.
Life Sciences now represents the largest end-market for ºÚÁϲ»´òìÈ. ºÚÁϲ»´òìÈ has invested over $400M over the last three years to build out its expertise and capability for pharmaceutical and biopharmaceutical customers, expanding to a team of more than 1,000 experts across 23 facilities in North America and Europe. This significant step change in pharmaceutical and medical testing capabilities from ºÚÁϲ»´òìÈ forms part of its broader strategic shift to increase its global presence and create leadership positions in Life Sciences and Connected Technologies end-markets.
Dr. Lackner is a highly experienced pharmaceutical and biotechnology executive and wellrespected global thought leader. She joins from Vineta, a family office focusing on long-term investments in Life Sciences, where she served as Managing Director. Prior to this she led the merger of ABF Pharmaceutical Services and GBA Group Pharma, serving as the CEO of the GBA Pharma Division. As CEO, she turned the company from a national vendor into an international trusted partner for the Pharma and Biotech industries. Dr. Lackner also serves as a QP (Qualified Person) and is a respected consultant in the life sciences industry. She holds a PhD in Pharmacy from the University of Vienna and a masters in Tumor Biology. She holds external positions on several boards, including Marinomed and Rivean Capital.
“We’re delighted to welcome Elisabeth to the leadership team of ºÚÁϲ»´òìÈ. Elisabeth joins us at a time of significant international expansion. She will play a key role in our ambitious growth strategy to support customers in the pharma, medtech and life sciences markets,” said Jo Wetz, CEO, ºÚÁϲ»´òìÈ. “In her new role as Chief Scientific Officer, Elisabeth will help us respond and mobilize to global trends affecting this industry, combining her scientific expertise and proven leadership skills. She joins an experienced international team, as we continue to grow both organically and through strategic M&A.”
Dr. Elisabeth Lackner commented: “It is exciting to be part of such an ambitious and professional team embarking on building new global offerings across a broad range of services in the life science industry, including research and development, diagnostics, analytical testing, manufacturing, regulatory assurance, calibration, and validation. I am looking forward to supporting customers throughout the lifecycle of their technology and products, from discovery and biopharma testing, to materials testing and manufacturing. With the ever-greater significance of advances in medical science and the importance of pharmaceutical and medical device development and commercialization, ºÚÁϲ»´òìÈ is ideally positioned to play an even greater role in supporting our customers across life sciences and beyond.”
Elisabeth will help ºÚÁϲ»´òìÈ to create a global platform for Life Sciences, with integrated support for the medicinal product and medical device industries. ºÚÁϲ»´òìÈ currently offers a wide range of services, including drug discovery; Biopharma testing (including E&L, microbiology and virology testing); environmental monitoring, calibration and validation; consumer product testing; medical device testing (including materials testing, E&L, microbiology, sterility, EMC and product safety); CRO services (including antimicrobial therapy development, central laboratory capabilities and bioanalytic testing); CDMO; and formulation services.
Over the past three years ºÚÁϲ»´òìÈ has successfully acquired and integrated several life science focused businesses, including ALG, Avomeen, Arch Sciences, Impact Analytical, Orthokinetic, Nanosyn JMI Laboratories and Clinimark. More information is available at www.element.com/life-sciences.
For a high-resolution image of Dr. Elisabeth Lackner, please contact element@mc-services.eu
About ºÚÁϲ»´òìÈ
The ºÚÁϲ»´òìÈ Group is one of the world’s leading global providers of testing, inspection and certification services for a diverse range of products, materials and technologies in advanced industrial supply chains where failure in use is not an option. Headquartered in London, UK, ºÚÁϲ»´òìÈ’s c 7,000 scientists, engineers and technologists, working in our global network of over 200 laboratories, support customers from early R&D, through complex regulatory approvals and into production ensuring their products are safe, sustainable and achieve market access.
In 2021, ºÚÁϲ»´òìÈ set out its new, industry leading environmental commitments, adopting science-based targets and committing to net zero emissions across its entire global business by 2035. These environmental commitments follow ºÚÁϲ»´òìÈ’s achievement of the highest ESG ranking in the testing, inspection and certification industry from Sustainalytics, a global leader in ESG research and data.
For more information about ºÚÁϲ»´òìÈ, please visit our website, connect with us on and and subscribe to our channel.
Contact
ºÚÁϲ»´òìÈ
Lee Andrews
E: Lee.Andrews@element.com
Media contacts
MC Services AG
Raimund Gabriel
T: +49 89 210228 0
UK : Shaun Brown
M: +44 7867 515 918
E: element@mc-services.eu